Enlivex Therapeutics Ltd. CEO Letter to Shareholders
Ticker: ENLV · Form: 6-K · Filed: Sep 11, 2025 · CIK: 1596812
Sentiment: neutral
Topics: ceo-letter, shareholder-update, foreign-private-issuer
TL;DR
Enlivex CEO dropped a shareholder letter on 9/11 with company updates.
AI Summary
On September 11, 2025, Enlivex Therapeutics Ltd. issued a letter from its CEO to shareholders. The letter provided an update on the company's progress and strategic initiatives. Enlivex Therapeutics Ltd. is a pharmaceutical preparations company based in Tel Aviv, Israel.
Why It Matters
This filing provides shareholders with an update directly from the CEO, offering insights into the company's current status and future direction.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- September 11, 2025 (date) — Date of CEO letter
- Tel Aviv, Israel (location) — Company Headquarters
- Bioblast Pharma Ltd. (company) — Former Company Name
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a letter from Enlivex Therapeutics Ltd.'s Chief Executive Officer to shareholders, providing an update on the company's progress and strategic initiatives.
When was the CEO's letter to shareholders issued?
The CEO's letter to shareholders was issued on September 11, 2025.
What is the principal executive office address of Enlivex Therapeutics Ltd.?
The principal executive office address is 14 Einstein Street, Nes Ziona, Israel 7403618.
What is Enlivex Therapeutics Ltd.'s SIC code?
Enlivex Therapeutics Ltd.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Has Enlivex Therapeutics Ltd. changed its name previously?
Yes, Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd., with a name change date of September 19, 2016, and prior to that, as BIO BLAST PHARMA LTD. with a name change date of January 13, 2014.
Filing Stats: 214 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2025-09-11 08:14:42
Filing Documents
- ea0256928-6k_enlivex.htm (6-K) — 9KB
- ea025692801ex99-1_enlivex.htm (EX-99.1) — 26KB
- ex99-1_001.jpg (GRAPHIC) — 19KB
- 0001213900-25-086674.txt ( ) — 64KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: September 11, 2025 2